{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:37Z","timestamp":1792525237605,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202206170028"],"award-info":[{"award-number":["202206170028"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00481-9","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:26:29Z","timestamp":1784863589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["eFAP-51, a novel FAPI dimer with enhanced tumor uptake and retention for theranostic applications"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4306-5359","authenticated-orcid":false,"given":"Le","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Stuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priciana","family":"Para\u00efso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Seimbille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"481_CR1","doi-asserted-by":"crossref","unstructured":"Ailabouni A, Prasad B. Organic cation transporters 2: Structure, regulation, functions, and clinical implications. Drug Metab Dispos. 2025;53(3).","DOI":"10.1016\/j.dmd.2025.100044"},{"key":"481_CR2","doi-asserted-by":"crossref","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S et al. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2). Pharmaceuticals (Basel). 2021;14(12).","DOI":"10.3390\/ph14121212"},{"issue":"1","key":"481_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Shahrnoy AA, Nami R, et al. Feasibility and therapeutic potential of [Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol I. 2024;52(1):237\u201346.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"24","key":"481_CR4","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1021\/jm800765e","volume":"51","author":"C Barinka","year":"2008","unstructured":"Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, et al. Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization. J Med Chem. 2008;51(24):7737\u201343.","journal-title":"J Med Chem"},{"issue":"9","key":"481_CR5","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1007\/s00259-025-07141-1","volume":"52","author":"A Bilinska","year":"2025","unstructured":"Bilinska A, Ballal S, Bal C, Lappchen T, Pilatis E, Menendez E, et al. Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study. Eur J Nucl Med Mol Imaging. 2025;52(9):3238\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"481_CR6","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1007\/s00259-025-07141-1","volume":"52","author":"A Bilinska","year":"2025","unstructured":"Bilinska A, Ballal S, Bal C, L\u00e4ppchen T, Pilatis E, Men\u00e9ndez E, et al. Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study. Eur J Nucl Med Mol I. 2025;52(9):3238\u201351.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"3","key":"481_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00259-025-07565-9","volume":"53","author":"A Bilinska","year":"2026","unstructured":"Bilinska A, Kumar N, Gnesin S, Lappchen T, Menendez E, Martin M, et al. Preclinical evaluation of DOTAGA.Glu.(FAPI)(2) and DO3A.Glu.(FAPI)(2) as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs. Eur J Nucl Med Mol Imaging. 2026;53(3):1887\u2013901.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"481_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10967-014-3248-1","volume":"302","author":"WAP Breeman","year":"2014","unstructured":"Breeman WAP, Chan HS, de Blois E. Determination of peptide content and purity of DOTA-peptides by metal ion titration and UPLC: an alternative method to monitor quality of DOTA-peptides. J Radioanal Nucl Chem. 2014;302(2):825\u201330.","journal-title":"J Radioanal Nucl Chem"},{"issue":"20","key":"481_CR9","doi-asserted-by":"publisher","first-page":"21739","DOI":"10.1021\/acs.jmedchem.5c02102","volume":"68","author":"P Brzeminski","year":"2025","unstructured":"Brzeminski P, Verhulst E, Fabisiak A, Pacifico R, Willocx D, Peeters S, et al. Structure-Property Investigation of New KetoFAPI Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential. J Med Chem. 2025;68(20):21739\u201365.","journal-title":"J Med Chem"},{"issue":"8015","key":"481_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"XY Cui","year":"2024","unstructured":"Cui XY, Li Z, Kong Z, Liu Y, Meng H, Wen Z, et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024;630(8015):206\u201313.","journal-title":"Nature"},{"issue":"2","key":"481_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.bbrc.2008.10.027","volume":"377","author":"L Ekerljung","year":"2008","unstructured":"Ekerljung L, Lindborg M, Gedda L, Frejd FY, Carlsson J, Lennartsson J. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Bioph Res Co. 2008;377(2):489\u201394.","journal-title":"Biochem Bioph Res Co"},{"key":"481_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/BST20160387","volume":"45","author":"B Erdogan","year":"2017","unstructured":"Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc T. 2017;45:229\u201336.","journal-title":"Biochem Soc T"},{"issue":"4","key":"481_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00259-024-06969-3","volume":"52","author":"A Galbiati","year":"2025","unstructured":"Galbiati A, Bocci M, Neri D, Cazzamalli S. Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics. Eur J Nucl Med Mol Imaging. 2025;52(4):1399\u2013405.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"481_CR14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2967\/jnumed.124.268200","volume":"65","author":"A Galbiati","year":"2024","unstructured":"Galbiati A, Bocci M, Ravazza D, Mock J, Gilardoni E, Neri D, et al. Preclinical Evaluation of 177 Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors. J Nucl Med. 2024;65(10):1604\u201310.","journal-title":"J Nucl Med"},{"issue":"12","key":"481_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","volume":"63","author":"A Galbiati","year":"2022","unstructured":"Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, et al. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake. J Nucl Med. 2022;63(12):1852\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"481_CR16","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","volume":"63","author":"A Galbiati","year":"2022","unstructured":"Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, et al. A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake. J Nucl Med. 2022;63(12):1852\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"481_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019;60(3):386\u201392.","journal-title":"J Nucl Med"},{"issue":"13","key":"481_CR18","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","volume":"48","author":"FL Giesel","year":"2021","unstructured":"Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, et al. Head-to-head intra-individual comparison of biodistribution and tumor uptake of Ga-FAPI and F-FDG PET\/CT in cancer patients. Eur J Nucl Med Mol I. 2021;48(13):4377\u201385.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"2","key":"481_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1389450122666210614121237","volume":"23","author":"MI Han","year":"2022","unstructured":"Han MI, Kucukguzel SG. Thioethers: An Overview. Curr Drug Targets. 2022;23(2):170\u2013219.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"481_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"1","key":"481_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s41181-024-00283-x","volume":"9","author":"CD van der Heide","year":"2024","unstructured":"Heide van der CD, Ma H, Hoorens MWH, Campeiro JD, Stuurman DC, de Ridder CMA, et al. In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions. EJNMMI Radiopharm Chem. 2024;9(1):55.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"481_CR22","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1021\/acs.bioconjchem.9b00206","volume":"30","author":"HM Hintz","year":"2019","unstructured":"Hintz HM, Cowan AE, Shapovalova M, LeBeau AM. Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma. Bioconjug Chem. 2019;30(5):1466\u201376.","journal-title":"Bioconjug Chem"},{"key":"481_CR63","doi-asserted-by":"crossref","unstructured":"Heide van der CD, Campeiro JD, Ruigrok EAM, van den Brink L, Ponnala S, Hillier SM et al. In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation. Ejnmmi Res. 2024;14(1).","DOI":"10.1186\/s13550-024-01191-6"},{"issue":"5","key":"481_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/ml300410d","volume":"4","author":"K Jansen","year":"2013","unstructured":"Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P, et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. Acs Med Chem Lett. 2013;4(5):491\u20136.","journal-title":"Acs Med Chem Lett"},{"issue":"6","key":"481_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nrc1094","volume":"3","author":"R Kalluri","year":"2003","unstructured":"Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3(6):422\u201333.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"481_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392\u2013401.","journal-title":"Nat Rev Cancer"},{"key":"481_CR26","doi-asserted-by":"publisher","first-page":"117513","DOI":"10.1016\/j.ejmech.2025.117513","volume":"290","author":"R Kochel","year":"2025","unstructured":"Kochel R, Wagner S, Schwegmann K, Schafers M, Breyholz HJ, Wunsch B. Synthesis of piperazine-based fluorinated fibroblast activation protein inhibitors for the development of a novel (18)F-labeled PET imaging probe. Eur J Med Chem. 2025;290:117513.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"481_CR27","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). Eur J Nucl Med Mol I. 2019;46(12):2536\u201344.","journal-title":"Eur J Nucl Med Mol I"},{"key":"481_CR28","doi-asserted-by":"crossref","unstructured":"K\u00f6chel R, Wagner S, Schwegmann K, Sch\u00e4fers M, Breyholz HJ, W\u00fcnsch B. Synthesis of piperazine-based fluorinated fibroblast activation protein inhibitors for the development of a novel 18F-labeled PET imaging probe. Eur J Med Chem. 2025;290.","DOI":"10.1016\/j.ejmech.2025.117513"},{"issue":"4","key":"481_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/cbic.201600612","volume":"18","author":"H van de Langemheen","year":"2017","unstructured":"Langemheen van de H, Korotkovs V, Bijl J, Wilson C, Kale SS, Heinis C, et al. Polar Hinges as Functionalized Conformational Constraints in (Bi) cyclic Peptides. ChemBioChem. 2017;18(4):387\u201395.","journal-title":"ChemBioChem"},{"key":"481_CR30","doi-asserted-by":"crossref","unstructured":"Lappchen T, Bilinska A, Pilatis E, Menendez E, Imlimthan S, Moon ES et al. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the (68)Ga- and (177)Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)(2). Molecules. 2024;29(13).","DOI":"10.3390\/molecules29133093"},{"issue":"9","key":"481_CR31","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"3","key":"481_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"YW Liu","year":"2022","unstructured":"Liu YW, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [Lu]FAPI-46 compared with [Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol I. 2022;49(3):871\u201380.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"9","key":"481_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"481_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/acs.jmedchem.4c02015","volume":"68","author":"Y Luo","year":"2024","unstructured":"Luo Y, Jin WB, Zang J, Wang GC, Zhu L, Kung HF. Development of [Ga]Ga\/[Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention. J Med Chem. 2024;68(1):348\u201360.","journal-title":"J Med Chem"},{"issue":"10","key":"481_CR35","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1021\/acs.bioconjchem.5c00218","volume":"36","author":"H Ma","year":"2025","unstructured":"Ma H, de Muynck L, Houvast RD, Beekman S, Piet A, March TL, et al. Revolutionizing Solid Tumor Surgery with Fibroblast Activation Protein (FAP)-Targeted Imaging Probes for a Fluorescence-Guided Surgery of Pancreatic Cancer. Bioconjug Chem. 2025;36(10):2145\u201357.","journal-title":"Bioconjug Chem"},{"issue":"20","key":"481_CR36","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","volume":"37","author":"M Mammen","year":"1998","unstructured":"Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Edit. 1998;37(20):2755\u201394.","journal-title":"Angew Chem Int Edit"},{"issue":"6","key":"481_CR37","first-page":"476","volume":"11","author":"ES Moon","year":"2021","unstructured":"Moon ES, Ballal S, Yadav MP, Bal C, Van Rymenant Y, Stephan S, et al. Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. Am J Nucl Med Molec. 2021;11(6):476\u2013.","journal-title":"Am J Nucl Med Molec"},{"issue":"3","key":"481_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cpet.2023.02.010","volume":"18","author":"S Mosessian","year":"2023","unstructured":"Mosessian S, Jensen JD, Enke AS. Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions. Pet Clin. 2023;18(3):429\u201339.","journal-title":"Pet Clin"},{"issue":"8","key":"481_CR39","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2967\/jnumed.124.267756","volume":"65","author":"R Mukkamala","year":"2024","unstructured":"Mukkamala R, Carlson DJ, Miller NK, Lindeman SD, Bowen ER, Tudi P, et al. Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios. J Nucl Med. 2024;65(8):1257\u201363.","journal-title":"J Nucl Med"},{"key":"481_CR40","doi-asserted-by":"crossref","unstructured":"Murce E, Beekman S, Spaan E, Handula M, Stuurman D, de Ridder C et al. Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer. Molecules. 2023;28(10).","DOI":"10.3390\/molecules28104022"},{"issue":"24","key":"481_CR41","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1002\/chem.200903281","volume":"16","author":"J Notni","year":"2010","unstructured":"Notni J, Hermann P, Havl\u00edckov\u00e1 J, Kotek J, Kub\u00edcek V, Plutnar J, et al. A Triazacyclononane-Based Bifunctional Phosphinate Ligand for the Preparation of Multimeric Ga Tracers for Positron Emission Tomography. Chem-Eur J. 2010;16(24):7174\u201385.","journal-title":"Chem-Eur J"},{"issue":"6","key":"481_CR64","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1053\/j.semnuclmed.2025.08.003","volume":"55","author":"AA \u00d6zt\u00fcrk","year":"2025","unstructured":"\u00d6zt\u00fcrk AA, Delbart W, Flamen P. Expanding the Horizon of Targeted Radionuclide Therapy: Immunotherapy Combinations and FAP- Targeted Approaches. Semin Nucl Med. 2025;55(6):999\u20131010.","journal-title":"Semin Nucl Med"},{"issue":"9","key":"481_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","volume":"64","author":"YZ Pang","year":"2023","unstructured":"Pang YZ, Zhao L, Fang JY, Chen JH, Meng LX, Sun L, et al. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy. J Nucl Med. 2023;64(9):1449\u201355.","journal-title":"J Nucl Med"},{"issue":"7","key":"481_CR43","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Prive","year":"2023","unstructured":"Prive BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol I. 2023;50(7):1906\u201318.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"3","key":"481_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1021\/acs.bioconjchem.3c00007","volume":"34","author":"SJ Raheem","year":"2023","unstructured":"Raheem SJ, Salih AK, Garcia MD, Sharpe JC, Toosi BM, Price EW. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [68Ga]Ga- DOTA-TATE Derivatives. Bioconjug Chem. 2023;34(3):549\u201361.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"481_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"481_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1021\/acsmedchemlett.4c00630","volume":"16","author":"K Saito","year":"2025","unstructured":"Saito K, Watanabe H, Nakashima K, Ono M. Preclinical Characterization of Novel FAP-2286-Based Radioligand with Albumin Binder for Improved Tumor Retention. Acs Med Chem Lett. 2025;16(4):596\u2013601.","journal-title":"Acs Med Chem Lett"},{"issue":"10","key":"481_CR47","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1021\/acs.molpharmaceut.5c00631","volume":"22","author":"K Saito","year":"2025","unstructured":"Saito K, Watanabe H, Yamaguchi K, Nakashima K, Ono M. Impact of Albumin-Binding Moieties on Structure-Affinity-Pharmacokinetic Relationships of Novel FAP-Targeting Radioligands. Mol Pharm. 2025;22(10):5989\u201398.","journal-title":"Mol Pharm"},{"issue":"12","key":"481_CR48","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1172\/JCI38988","volume":"119","author":"AM Santos","year":"2009","unstructured":"Santos AM, Jung J, Aziz N, Kissil JL, Pur\u00e9 E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119(12):3613\u201325.","journal-title":"J Clin Invest"},{"issue":"12","key":"481_CR49","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan MJ, Raj BKM, Calvo B, Garinchesa P, Sanzmoncasi MP, Healey JH, et al. Molecular-Cloning of Fibroblast Activation Protein-Alpha, a Member of the Serine-Protease Family Selectively Expressed in Stromal Fibroblasts of Epithelial Cancers. P Natl Acad Sci USA. 1994;91(12):5657\u201361.","journal-title":"P Natl Acad Sci USA"},{"key":"481_CR50","doi-asserted-by":"crossref","unstructured":"Tan Y, Li J, Zhao TZ, Xu PF, Chen XY, Zhang JJ. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. J Nucl Med. 2024;65.","DOI":"10.1007\/s00259-024-06703-z"},{"issue":"1","key":"481_CR51","doi-asserted-by":"publisher","first-page":"e202500366","DOI":"10.1002\/open.202500366","volume":"15","author":"A Ten","year":"2026","unstructured":"Ten A, Koizhaiganova R, Bissenbay D, Tursynova B, Zhaxibayeva Z, Yu V. Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry. ChemistryOpen. 2026;15(1):e202500366.","journal-title":"ChemistryOpen"},{"issue":"3","key":"481_CR52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1124\/dmd.32.3.333","volume":"32","author":"KA Usmani","year":"2004","unstructured":"Usmani KA, Karoly ED, Hodgson E, Rose RL. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab Dispos. 2004;32(3):333\u20139.","journal-title":"Drug Metab Dispos"},{"key":"481_CR53","doi-asserted-by":"publisher","first-page":"118494","DOI":"10.1016\/j.ejmech.2025.118494","volume":"304","author":"E Verhulst","year":"2026","unstructured":"Verhulst E, Brzeminski P, de Groot A, Wals JW, Michiels R, Fabisiak A, et al. In vitro kinetic profiling by enzymatic approaches to select FAPIs with a long residence time. Eur J Med Chem. 2026;304:118494.","journal-title":"Eur J Med Chem"},{"issue":"13","key":"481_CR54","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","volume":"66","author":"YW Wang","year":"2023","unstructured":"Wang YW, Yuan HM, Liu N, Tang SF, Feng Y, Liu Y, et al. High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors. J Med Chem. 2023;66(13):8614\u201327.","journal-title":"J Med Chem"},{"issue":"13","key":"481_CR55","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00259-021-05470-5","volume":"48","author":"SL Wang","year":"2021","unstructured":"Wang SL, Zhou X, Xu XX, Ding J, Liu S, Hou XG, et al. Clinical translational evaluation of Al F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol I. 2021;48(13):4259\u201371.","journal-title":"Eur J Nucl Med Mol I"},{"key":"481_CR56","doi-asserted-by":"crossref","unstructured":"Wang YL, Zhou HM, Ju SG, Dong XJ, Zheng CS. The solid tumor microenvironment and related targeting strategies: a concise review. Front Immunol. 2025;16.","DOI":"10.3389\/fimmu.2025.1563858"},{"issue":"9","key":"481_CR57","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1016\/j.apsb.2025.07.009","volume":"15","author":"YX Wu","year":"2025","unstructured":"Wu YX, Wang XK, Sun XN, Gao X, Zhang SQ, Shen JT, et al. Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation. Acta Pharm Sin B. 2025;15(9):4511\u201342.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"481_CR58","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","volume":"51","author":"MP Yadav","year":"2024","unstructured":"Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, et al. Therapeutic potential of [Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment. Eur J Nucl Med Mol I. 2024;51(3):805\u201319.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"8","key":"481_CR59","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1021\/acs.molpharmaceut.5c00464","volume":"22","author":"HM Yuan","year":"2025","unstructured":"Yuan HM, Li HY, Wu TT, Tang SF, Wang YW, Yang ZC, et al. Structural Optimization of Fibroblast Activation Protein Inhibitors Through Zwitterionic and PEG Modification Strategy: Impact on Pharmacokinetics and Tumor Imaging. Mol Pharmaceut. 2025;22(8):4831\u201343.","journal-title":"Mol Pharmaceut"},{"issue":"11","key":"481_CR60","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3651\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"481_CR61","doi-asserted-by":"crossref","unstructured":"Zboralski D, Osterkamp F, von Hacht JL, Bredenbeck A, Hohne A, Libera-Korner J et al. Preclinical Development of 3BP-3940, a Fibroblast Activation Protein-Targeted Cyclic Peptide-Based Radiotheranostic for Imaging and Therapy. J Nucl Med. 2026.","DOI":"10.2967\/jnumed.125.271452"},{"key":"481_CR62","doi-asserted-by":"crossref","unstructured":"Zhao L, Pang YZ, Lin Q, Chen HJ. Antitumor Efficacy and Potential Mechanism of FAP-targeted Radioligand Therapy Combined with Immune Checkpoint Blockade: From Bench to Bedside. J Nucl Med. 2024;65.","DOI":"10.1038\/s41392-024-01853-w"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00481-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:33Z","timestamp":1792522953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00481-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00481-9","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki. Approval was granted by the Animal Welfare Committee of the Erasmus MC (CCD#: 2216075, SP2400006).","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"79"}}